- Q4 2023 Alligator Bioscience AB Earnings Call TranscriptFeb 09, 2024kr1.16Earnings
- Q2 2023 Alligator Bioscience AB Earnings Call TranscriptJul 13, 2023kr0.380565 (-6.15%)Earnings
- Q1 2023 Alligator Bioscience AB Earnings Call TranscriptApr 25, 2023kr0.54311Earnings
- Q4 2022 Alligator Bioscience AB Earnings Call TranscriptFeb 10, 2023kr0.733614Earnings
- Q3 2022 Alligator Bioscience AB Earnings Call TranscriptOct 20, 2022kr0.539375Earnings
- Alligator Bioscience AB at Redeye Growth Day (Virtual) TranscriptJun 02, 2022
- Q1 2022 Alligator Bioscience AB Earnings Call TranscriptApr 27, 2022kr0.758746Earnings
- Q4 2021 Alligator Bioscience AB Earnings Call TranscriptFeb 11, 2022kr0.942198Earnings
- Q3 2021 Alligator Bioscience AB Earnings Call TranscriptOct 22, 2021kr0.730733Earnings
- Q2 2021 Alligator Bioscience AB Earnings Call TranscriptJul 13, 2021kr1.62Earnings
- Q4 2020 Alligator Bioscience AB Earnings Call TranscriptFeb 26, 2021kr1.62Earnings
- Alligator Bioscience AB at Biostock Life Science Summit (Virtual) TranscriptNov 18, 2020
- Q3 2020 Alligator Bioscience AB Earnings Call TranscriptOct 22, 2020kr1.76Earnings
- Alligator Bioscience AB R&D Market Update TranscriptAug 27, 2020
- Alligator Bioscience AB at AACR Virtual Annual Meeting TranscriptApr 27, 2020
- Q4 2019 Alligator Bioscience AB Earnings Call TranscriptFeb 12, 2020kr1.93Earnings
Alligator Bioscience AB at Biostock Life Science Summit (Virtual) Transcript
-- where our next presenter is Per Norlen, CEO of Alligator Bioscience. Welcome, Per.
Thank you. All right. We're ready to go.
Go ahead.
So thank you so much. Alligator is a clinical stage public immuno-oncology biotech company. And I would like straight to the company highlights. So Alligator has generated five clinical stage programs built on our own technology platforms. We have a very strong innovation track record, and we brought them all the way from ID to clinical stage.
Today, we focus on two of these assets, lead asset assets that are moving into clinical Phase 2. And those two assets are optimized for best and first-in-class profile, and which is supported by a very strong preclinical and clinical package. We have also studies coming up already in 2021, and I will come back to this soon.
Also
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)